Is it Beneficial to Treat Patients Presenting Three Weeks or Longer after the Onset of Sudden Sensorineural Hearing Loss?
Journal
The journal of international advanced otology
ISSN: 2148-3817
Titre abrégé: J Int Adv Otol
Pays: Turkey
ID NLM: 101522982
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
23
9
2021
Statut:
ppublish
Résumé
The accepted treatment for idiopathic sudden sensorineural hearing loss (ISSNHL) consists of oral or intratympanic steroids. The time from onset to treatment is considered as an important prognostic factor, although there is no clear cutoff point when treatment is no longer beneficial. This study aimed to assess the efficacy of treatment with oral or intratympanic steroids and carbogen, in patients presenting 21 days or later after the onset of hearing loss. A total of 895 patients with ISSNHL was seen in our center between 2010 and 2018. The study cohort included 103 patients treated with oral or intratympanic steroids or both with carbogen 21 days or longer after experiencing hearing loss. Retrospective analysis of files and audiometry was conducted, and pre- and post-treatment audiograms were compared. Improvement was defined by SRT (≥15 dB improvement), discrimination (≥15% improvement), or 15 dB improvement at specific frequencies (250-500, 4000-6000 Hz). Hearing improvement, according to the study definition, was seen in 22.3% (23/103) of patients within the time period of the treatment. All the 23 patients had functional hearing after treatment and 16 of them returned to their baseline or normal hearing. While the time from onset of ISSNHL to treatment varied, most patients demonstrating improvement were treated 21-30 days after onset. In this patient cohort treated late for sudden sensorineural hearing loss (SSNHL), a small but significant number of patients improved during the time of treatment. Although the lack of a control group makes it difficult to prove that the improvement resulted from the treatment, we recommend not to rule out treatment systematically in patients presenting late after ISSNHL. Additional prospective studies are warranted.
Identifiants
pubmed: 33136011
doi: 10.5152/iao.2020.8489
pmc: PMC7901470
doi:
Substances chimiques
Glucocorticoids
0
Dexamethasone
7S5I7G3JQL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
323-327Références
Ann Otol Rhinol Laryngol. 1977 Jul-Aug;86(4 Pt 1):463-80
pubmed: 889223
Otolaryngol Head Neck Surg. 2012 Mar;146(3 Suppl):S1-35
pubmed: 22383545
Arch Otolaryngol. 1980 Dec;106(12):772-6
pubmed: 7002129
J Laryngol Otol. 2017 Jan;131(1):77-82
pubmed: 27917721
Laryngoscope. 2015 Jan;125(1):209-17
pubmed: 25045896
Otol Neurotol. 2008 Jun;29(4):464-9
pubmed: 18434930
Otol Neurotol. 2003 Sep;24(5):728-33
pubmed: 14501447
Laryngoscope. 1984 May;94(5 Pt 1):647-61
pubmed: 6325838
J Int Adv Otol. 2018 Aug;14(2):166-169
pubmed: 30100544
Indian J Otolaryngol Head Neck Surg. 2012 Mar;64(1):1-4
pubmed: 23448732
N Engl J Med. 2008 Aug 21;359(8):833-40
pubmed: 18716300
Acta Otolaryngol. 2007 Nov;127(11):1168-75
pubmed: 17851927